- Opinion
- [Column] Legal disputes over rebate penalty reducing price
- by Lee, Hye-Kyung Dec 5, 2019 06:12am
- This year would be a year to remember as various issues regarding drug pricing broke out, such as ‘lump-sum price reduction on single-use eye drops’, ‘revised generic pricing system’, and ‘litigation against pricing reduction penalty for providing rebate’. Currently the drug pricing system is geared towards paradigm shift, starting
- InterView
- “Independent Galderma aims for both innovation and jobs”
- by Eo, Yun-Ho Dec 4, 2019 06:43am
- Global pharmaceutical companies are flexible with corporate merger and business acquisition. They are not afraid to take a better choice to survive and advance forward in ever-changing trend. Although such drastic changes cause restructure, downsizing and other issues, global companies have constantly taken the path of changes so far.
- Company
- Ildong exclusively sells 9 kinds of GSK generic drugs
- by Chon, Seung-Hyun Dec 4, 2019 06:41am
- Ildong Pharmaceuticals announced on the 2nd that it has signed 9 co-promotional contracts with GlaxoSmithKline Consumer Healthcare Korea, including general medicines. With this agreement, Ildong Pharmaceuticals is a comprehensive cold medicine ‘ theraflu’, an ophthalmic drug ‘Otrivin’, a non-smoking supplement ‘Nicotinell’, a hyperhidr
- Company
- Narcolepsy treatment, Nuvigil settled down in Big 5 hospital
- by Eo, Yun-Ho Dec 4, 2019 06:41am
- Narcolepsy treatment, Nuvigil are facing the entry in Big 5 hospitals. According to the industry, Handokteva's Nuvigil (Amordafinil) has passed the SNUH, Severance Hospital, SMC, and ASAN Medical Center's drug commitee (DC). In addition, prescription code was generated at St. Vincent's Hospital of Catholic University. The system of St.
- Company
- Vyndaqel quick to request for ATTR-CM indication
- by Eo, Yun-Ho Dec 3, 2019 08:14pm
- In Korea, a rare disease treatment, Vyndaqel is applying for an expanded use in patients with transthyretin amyloid cardiomyopathy (ATTR-CM). In September, Pfizer Korea submitted an application to Ministry of Food and Drug Safety (MFDS) for approval on expanded indication for Vyndaqel, currently approved for treating hereditary transthy
- Company
- 8 multinational companies name new CEOs in Korea
- by Eo, Yun-Ho Dec 3, 2019 03:21pm
- Sources report eight global pharmaceutical companies have appointed new CEOs of Korean affiliates this year only. Daily Pharm surveyed a roster of major 30 multinational companies’ Korean affiliate CEOs as of Dec. 4, and found about 28 percent of the companies have either replaced or newly appointed the top executive personnel. Whi
- Policy
- Opdivo label changes but reimbursed scope unchanged
- by Lee, Hye-Kyung Dec 3, 2019 05:55am
- Ono Pharmaceutical’s immunotherapy Opdivo’s (nivolumab) 240 mg dose secured an approval from the regulator and expanded scope of administration on the label, but apparently the treatment’s reimbursed level of dose would remain unchanged. Health Insurance Review and Assessment Service (HIRA) recently collected public comments on the r
- Policy
- Hyperalgesia possibility if Fentanyl mucosa not control pain
- by Lee, Tak-Sun Dec 3, 2019 05:54am
- Fentanyl mucosal drug, a typical narcotic analgesic used for the treatment of cancer patients, may not be controlled by hyperalgesia and resistance, will be reflected in the permit. This was done by the Agency by reviewing safety information from the European Medicines Agency (EMA). The permission change adds that fentanyl mucosal medic
- Company
- Counterattack of Valsartan’s Pharmaceuticals
- by Chon, Seung-Hyun Dec 3, 2019 05:54am
- Pharmaceuticals filed an alleged class action lawsuit against health authorities. A lawsuit was filed preemptively that the government can not accept the Valsartan claim. Cost liability for follow-up of impurity drugs has been determined in court. According to the industry, 36 pharmaceutical companies recently filed a lawsuit to confirm th
- Company
- ECCK “Revised Pricing Negotiation Guideline Violates FTA"
- by Kim, Jin-Gu Dec 3, 2019 05:53am
- Europe-based global pharmaceutical companies with offshoots in Korea have filed official complaints on ‘additional requirements under side agreement’ added to drug pricing negotiation procedure in Korea. They claim the new changes could violate the principles of Korea-EU Free Trade Agreement (FTA). European Chamber of Commerce in Ko
